Child Kidney Dis.  2022 Dec;26(2):97-100. 10.3339/ckd.22.034.

Hypertensive crisis following mRNA COVID-19 vaccination in adolescents: two case reports

• Cho MH
• Cheong HI

• KMID: 2538741
• DOI: http://doi.org/10.3339/ckd.22.034

Abstract

In response to the global coronavirus disease 2019 (COVID-19) pandemic, vaccines were developed and approved quickly. However, numerous cardiovascular adverse events have been reported. We present two adolescent cases who developed a hypertensive crisis following NT162b2 mRNA COVID-19 vaccination. Patient 1 was an 18-year-old male and his systolic blood pressure was 230 mmHg one day after the second vaccine. He was obese. No secondary cause of hypertension other than the vaccine was identified. Patient 2 was an 18-year-old male who complained with palpitation after the first vaccine. His blood pressure was 178/109 mmHg. He had autosomal dominant polycystic kidney disease. Both were treated with continuous infusion of labetalol followed by losartan, and blood pressure was controlled. Patient 2 received second vaccination and his blood pressure did not rise. It is warranted to measure blood pressure in adolescents at high risk of hypertension after NT162b2 mRNA COVID-19 vaccination.

Keyword

Adolescent; Blood pressure; Case reports; COVID-19 vaccines; Hypertension; Messenger RNA

Reference

References

1. Raina R, Mahajan Z, Sharma A, Chakraborty R, Mahajan S, Sethi SK, et al. Hypertensive crisis in pediatric patients: an overview. Front Pediatr. 2020; 8:58891.

2. Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G, et al. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension. 2021; 77:e56–7.

3. Athyros VG, Doumas M. A possible case of hypertensive crisis with intracranial haemorrhage after an mRNA anti-COVID-19 vaccine. Angiology. 2022; 73:87.

4. Kim MS, Jung SY, Ahn JG, Park SJ, Shoenfeld Y, Kronbichler A, et al. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: a pharmacovigilance analysis using WHO international database. J Med Virol. 2022; 94:1085–95.

5. Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 vaccines: much accomplished, much to learn. Ann Intern Med. 2021; 174:687–90.

6. Pucci F, Annoni F, Dos Santos RA, Taccone FS, Rooman M. Quantifying renin-angiotensin-system alterations in COVID-19. Cells. 2021; 10:2755.

7. Mizuiri S, Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol. 2015; 4:74–82.

8. Schrier RW. Decade in review--polycystic kidney disease: slowing progression of autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2015; 11:638–9.

9. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019; 15:367–85.

10. Khani E, Entezari-Maleki T. Hypertensive crisis following COVID-19 vaccination. J Clin Pharmacol. 2022; 62:1047–8.